Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: Clinical and biological significance

Journal of B.U.ON.

Volumn 19, Issue 1, 2014, Pages 215-220

  Hu, Chuanyi ^a   Jiang, Ning ^a   Wang, Guozeng ^a   Zheng, Jingcun ^a   Yang, Wei ^a   Yang, Jiawei ^a  

^a Department of Urology Shanghai Pundong New Area Gongli Hospital   (China)

Author keywords

Hepatocyte growth factor activator inhibitor type l(HAI l); Metastasis; Prognosis; Prostate cancer

Indexed keywords

HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; MESSENGER RNA; SCATTER FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; GENE EXPRESSION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR GENE;

AGED; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; TUMOR MARKERS, BIOLOGICAL;

EID: 84898870317     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. (Pubitemid 46148091)
2. Plantade A, Massard C, de Crevoisier R, Fizazi K. Locally advanced prostate cancer: definition, prognosis and treatment (in French). Bull Cancer 2007;94:50-61.
3. Utomo NB, Mochtar CA, Umbas R. Primary hormonal treatment in localized and locally advanced prostate cancer: effectiveness and survival predictive factors. Acta Med Indones 2012;44:10-15.
4. Dasgupta S, Srinidhi S, Vishwanatha JK. Oncogenic activation in prostate cancer progression and metastasis: molecular insights and future challenges. J Carcinog 2012;11:4-7.
5. Shimomura T, Denda K, Kitamura A et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997;272:6370-6376. (Pubitemid 27118113)
6. Eigenbrot C, Ganesan R, Kirchhofer D. Hepatocyte growth factor activator (HGFA): molecular structure and interactions with HGFA inhibtor-1 (HAI-1). FEBS J 2010;277:2215-2222.
7. Kataoka H, Kawaguchi M. Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo. FEBS J 2010;277:2230-2237.
8. Parr C, Jiang WG. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer 2006;119:1176-1183. (Pubitemid 44116927)
9. Benaud CM, Oberst M, Dickson RB et al. Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 2002;19:639-649. (Pubitemid 35454575)
10. Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 1975;2:105-124.
11. General Rule for Clinical and Pathological Studies on Prostate Cancer. The Japanese Urological Association, the Japanese Society of Pathology, and Japan Radiological Society (3rd Edn). Kanehara-shuppan, Tokyo, 2001, pp 44-45.
12. Sanders AJ, Parr C, Mason MD, Jiang WG. Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med 2007;20:613-619.
13. Andrew J, Sanders S, Christian P, Malcolm D, Mason, Weng J. Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med 2007;20:613-619.
14. Saleem M, Adhami VM, Zhong W et al. A novel biomarker for staging human prostate abenocarcinoma: Overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Pev 2006; 15: 217-227. (Pubitemid 43342167)
15. Parr C, Jiang WG. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer 2006;119:1176-1183. (Pubitemid 44116927)
16. Nakamura K, Abarzua F, Hongo A et al. The role of hepatocyte growth factor activator inhibitor-1 (HAI- 1) as a prognostic indicator in cervical cancer. Int J Oncol 2009;35:239-248.
17. Nakamura K, Hongo A, Kodoma J, Hiramatsu Y. The role of hepatocyte growth factor activator inhibitor (HAI)-2 in endometrial cancer. Int J Cancer 2009;35: 239-248.
18. Parr C. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer 2006;119: 1176-1183. (Pubitemid 44116927)
19. Miyata S, Fukushima T, Kohama K, Tanaka H, Takeshima H, Kataoka H. Roles of Kunitz domains in the anti-invasive effect of hepatocyte growth factor activator inhibitor type 1 in human glioblastoma cells. Hum Cell 2007;20:100-106. (Pubitemid 47621823)
20. Fukushima T, Kawaguchi M, Yamasaki M. Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells. Cancer Sci 2011;102:407-408.
21. Keiichiro N,Atsushi HJunichi K.Yuji H.The role of hepatocyte growth factor activator inhibitor(HAI)-l and HAI-2 in endometrial cancer. Int J Cancer 2011;128:2613-2624.
22. Nakamura K, Abarzua F, Hongo A et al. Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma. Int J Oncol 2010;37:605-614.
23. Keiichiro N.Femando A,Atsushi H et al. The role of hepatocyte growth factor activator inhibitor-l(HAI-l) as a prognostic indicator in cervical cancer. Int J Oncol 2009;35:239-248.